304 related articles for article (PubMed ID: 38428879)
1. Advances in tumor immune microenvironment of head and neck squamous cell carcinoma: A review of literature.
Hong Q; Ding S; Xing C; Mu Z
Medicine (Baltimore); 2024 Mar; 103(9):e37387. PubMed ID: 38428879
[TBL] [Abstract][Full Text] [Related]
2. Immune microenvironment of human papillomavirus-positive head and neck squamous cell carcinoma.
Zhu D; He X; Li Y; Li G; Chen M
Sci Prog; 2024; 107(1):368504241237888. PubMed ID: 38545800
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive investigation into the influence of glycosylation on head and neck squamous cell carcinoma and development of a prognostic model for risk assessment and anticipating immunotherapy.
Ma H; Xiong L; Zhao B; Hahan Z; Wei M; Shi H; Yang S; Ren Q
Front Immunol; 2024; 15():1364082. PubMed ID: 38562924
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
5. Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
Farlow JL; Brenner JC; Lei YL; Chinn SB
Oral Oncol; 2021 Sep; 120():105420. PubMed ID: 34218062
[TBL] [Abstract][Full Text] [Related]
6.
Wei Z; Shen Y; Zhou C; Cao Y; Deng H; Shen Z
Bioengineered; 2022 May; 13(5):13784-13800. PubMed ID: 35712757
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
[TBL] [Abstract][Full Text] [Related]
8. Tumor immune microenvironment in head and neck cancers.
Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH
Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286
[TBL] [Abstract][Full Text] [Related]
9. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the immune cell function landscape in head and neck squamous carcinoma to assist in prognosis prediction and immunotherapy.
Wang W; Zhang Z; Li W; Wei D; Xu J; Qian Y; Cao S; Lei D
Aging (Albany NY); 2023 Nov; 15(21):12588-12617. PubMed ID: 37955651
[TBL] [Abstract][Full Text] [Related]
11. Mast cell marker gene signature in head and neck squamous cell carcinoma.
Cai Z; Tang B; Chen L; Lei W
BMC Cancer; 2022 May; 22(1):577. PubMed ID: 35610596
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Head and Neck Cancer.
Sim F; Leidner R; Bell RB
Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
15. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
Front Immunol; 2021; 12():757047. PubMed ID: 34675936
[TBL] [Abstract][Full Text] [Related]
16. Insights into metastatic roadmap of head and neck cancer squamous cell carcinoma based on clinical, histopathological and molecular profiles.
Mastronikolis NS; Delides A; Kyrodimos E; Piperigkou Z; Spyropoulou D; Giotakis E; Tsiambas E; Karamanos NK
Mol Biol Rep; 2024 Apr; 51(1):597. PubMed ID: 38683372
[TBL] [Abstract][Full Text] [Related]
17. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.
Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799
[TBL] [Abstract][Full Text] [Related]
18. An ion-channel-gene-based prediction model for head and neck squamous cell carcinoma: Prognostic assessment and treatment guidance.
Han Y; Shi Y; Chen B; Wang J; Liu Y; Sheng S; Fu Z; Shen C; Wang X; Yin S; Li H
Front Immunol; 2022; 13():961695. PubMed ID: 36389709
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy for head and neck squamous cell carcinoma].
Chen J; Chen M; Wu HT
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 52(2):143-147. PubMed ID: 28219181
[TBL] [Abstract][Full Text] [Related]
20. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
